Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Receives $16.00 Average PT from Brokerages

Shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA) have received an average recommendation of “Buy” from the nine analysts that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, six have given a buy rating and two have assigned a strong buy rating to the company. The average 12-month price target among analysts that have covered the stock in the last year is $16.00.

Several research firms recently weighed in on IVA. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Inventiva in a report on Tuesday, September 30th. Guggenheim dropped their price target on shares of Inventiva from $13.00 to $11.00 and set a “buy” rating on the stock in a research report on Tuesday, November 18th. HC Wainwright increased their price objective on shares of Inventiva from $20.00 to $24.00 and gave the company a “buy” rating in a report on Thursday, October 9th. Leerink Partners began coverage on shares of Inventiva in a research note on Monday, January 12th. They set an “outperform” rating and a $12.00 price objective on the stock. Finally, UBS Group began coverage on Inventiva in a research report on Wednesday, January 7th. They issued a “buy” rating and a $12.00 target price for the company.

Inventiva Trading Down 1.1%

Shares of IVA stock opened at $7.07 on Friday. Inventiva has a 1 year low of $2.15 and a 1 year high of $7.98. The stock has a fifty day moving average of $4.86 and a two-hundred day moving average of $4.73.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of IVA. Wealth Enhancement Advisory Services LLC raised its position in Inventiva by 54.5% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 16,558 shares of the company’s stock worth $50,000 after acquiring an additional 5,843 shares in the last quarter. Creative Planning acquired a new position in shares of Inventiva in the 2nd quarter worth approximately $32,000. NewEdge Advisors LLC acquired a new position in shares of Inventiva in the 3rd quarter worth approximately $116,000. Finally, Millennium Management LLC bought a new stake in shares of Inventiva in the 3rd quarter worth approximately $649,000. 19.06% of the stock is owned by institutional investors and hedge funds.

Inventiva Company Profile

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.